Objective:

To urgently address the significant gap between therapeutic innovation and evidence in glaucoma treatment.

Key Findings:

• There is a significant gap between the pace of innovation and the ability to conduct robust trials in glaucoma, as evidenced by recent studies.
• Registry-based trials could streamline data collection and increase participation without the need for extensive infrastructure, as shown in preliminary trials.
• New statistical tools like WIN ratios and Fragility Indices are gaining traction and could improve the quality of trial reporting, as discussed in recent conferences.

Interpretation:

The field of glaucoma requires a critical shift towards collaborative efforts and innovative trial designs to effectively evaluate new treatments and improve patient outcomes.

Limitations:

• Current trials often lack the strength needed for definitive conclusions due to insufficient collaboration, leading to inconclusive results.
• The implementation of new statistical tools and AI is not yet standardized in clinical practice, which may hinder their effectiveness.

Conclusion:

Improving collaboration and adopting innovative trial methodologies are essential for advancing glaucoma treatment and ensuring robust evidence, ultimately benefiting patient care.